Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Longevity |
| Evidence grade | Limited |
| Also known as | Epithalon, AEDG peptide |
| Mechanism | Proposed to induce telomerase reverse transcriptase expression, allowing telomere elongation in somatic cells, and to normalise melatonin rhythm through pineal action. |
| Key benefits | Telomere lengthening reported in cell culture · Improved sleep–wake rhythm · Longevity signals in long-running Russian cohort studies |
| Side effects | Sparse safety data · Occasional drowsiness · Injection-site reaction |
| Half-life | Minutes — effects attributed to gene expression rather than plasma level |
| Administration | Subcutaneous injection; intranasal versions exist |
| Dosing overview | 5–10 mg daily for 10–20 days, cycled 1–3 times per year |
| Storage | Reconstituted vials refrigerated and used within the cycle |
| Legal status | Not approved outside of Russia/CIS research contexts. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.